HEMOPHILIA A AND B
-
Return of Octostim spray delayed until late 2024
In a letter to the European Haemophilia Consortium dated May 31, 2022, Ferring Pharmaceuticals informed the bleeding disorder community that Octostim (desmopressin) Nasal Spray 1.5...
-
CHS reacts to Health Canada decision on relaxing donor selection criteria
April 28, 2022 (Montreal) – “The Canadian Hemophilia Society (CHS) is disappointed that Health Canada has not followed our advice regarding the changes to donor...
-
Committed BC health care providers receive two awards
by Wendy Quinn, CHS President A few days ago I received an e-mail with the subject “Exciting news and accomplishments in BC.” I immediately opened...
-
CBS supplier contracts for rFVIII and rFIX take effect April 4
March 30, 2022, Ottawa – Canadian Blood Services’ contracts with suppliers of recombinant factor VIII and IX for the 2022-2025 period take effect on April...
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...